Patents by Inventor Cosmo FEILDING-MELLEN

Cosmo FEILDING-MELLEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACEUTICAL COMPOSITION COMPRISING 5-METHOXY-N,N-DIMETHYLTRYPTAMINE
    Publication number: 20230382858
    Abstract: An intranasal composition comprising a dosage amount of 50-150 mg/ml 5-methoxy-N,N-dimethyltryptamine (5MeODMT) in a liquid medium, wherein the 5MeODMT is formulated as the chloride salt of 5MeODMT (5MeODMT hydrochloride) and wherein the 5MeODMT hydrochloride is crystalline and characterised by one or more of: peaks in an XRPD diffractogram; an endothermic event in a DSC thermograph; an onset of decomposition in a TGA thermograph; and a DVS isotherm profile.
    Type: Application
    Filed: May 2, 2023
    Publication date: November 30, 2023
    Applicant: Beckley Psytech Limited
    Inventors: Cosmo FEILDING-MELLEN, Timothy MASON
  • COMPOSITION COMPRISING A BENZOATE SALT OF 5-METHOXY-N,N-DIMETHYLTRYPTAMINE
    Publication number: 20230348381
    Abstract: A composition comprising a pharmaceutically effective amount of a pharmaceutically acceptable benzoate salt of 5-methoxy-N,N-dimethyltryptamine (5MeODMT).
    Type: Application
    Filed: February 1, 2023
    Publication date: November 2, 2023
    Applicant: Beckley Psytech Limited
    Inventors: Cosmo FEILDING-MELLEN, Timothy MASON
  • PHARMACEUTICAL COMPOSITION COMPRISING 5-METHOXY-N,N-DIMETHYLTRYPTAMINE
    Publication number: 20230031944
    Abstract: An intranasal composition comprising a dosage amount of 50-150 mg/ml 5-methoxy-N,N-dimethyltryptamine (5MeODMT) in a liquid medium, wherein the 5MeODMT is formulated as the chloride salt of 5MeODMT (5MeODMT hydrochloride) and wherein the 5MeODMT hydrochloride is crystalline and characterised by one or more of: peaks in an XRPD diffractogram; an endothermic event in a DSC thermograph; an onset of decomposition in a TGA thermograph; and a DVS isotherm profile.
    Type: Application
    Filed: September 26, 2022
    Publication date: February 2, 2023
    Applicant: Beckley Psytech Limited
    Inventors: Cosmo FEILDING-MELLEN, Timothy MASON
  • COMPOSITION COMPRISING A BENZOATE SALT OF 5-METHOXY-N,N-DIMETHYLTRYPTAMINE
    Publication number: 20220396552
    Abstract: A composition comprising a pharmaceutically effective amount of a pharmaceutically acceptable benzoate salt of 5-methoxy-N,N-dimethyltryptamine (5MeODMT).
    Type: Application
    Filed: August 4, 2022
    Publication date: December 15, 2022
    Applicant: Beckley Psytech Limited
    Inventors: Cosmo FEILDING-MELLEN, Timothy MASON
  • PHARMACEUTICAL COMPOSITION COMPRISING 5-METHOXY-N,N-DIMETHYLTRYPTAMINE
    Publication number: 20220267267
    Abstract: An intranasal composition comprising a dosage amount of 50-150 mg/ml 5-methoxy-N,N-dimethyltryptamine (5MeODMT) in a liquid medium, wherein the 5MeODMT is formulated as the chloride salt of 5MeODMT (5MeODMT hydrochloride) and wherein the 5MeODMT hydrochloride is crystalline and characterised by one or more of: peaks in an XRPD diffractogram; an endothermic event in a DSC thermograph; an onset of decomposition in a TGA thermograph; and a DVS isotherm profile.
    Type: Application
    Filed: April 27, 2022
    Publication date: August 25, 2022
    Inventor: Cosmo FEILDING-MELLEN
  • COMPOSITION COMPRISING A BENZOATE SALT OF 5-METHOXY-N,N-DIMETHYLTRYPTAMINE
    Publication number: 20220259147
    Abstract: A composition comprising a pharmaceutically effective amount of a pharmaceutically acceptable benzoate salt of 5-methoxy-N,N-dimethyltryptamine (5MeODMT).
    Type: Application
    Filed: April 27, 2022
    Publication date: August 18, 2022
    Inventor: Cosmo FEILDING-MELLEN